echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Hengrui's CDK4/6 inhibitor is reported to be listed for priority review

    Hengrui's CDK4/6 inhibitor is reported to be listed for priority review

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    SHR6390 is a class 1 new drug developed by Jiangsu Hengrui Pharmaceutical Co.


    On December 24 last year, Hengrui announced that SHR6390 combined with fulvestrant in the treatment of HR-positive, HER2-negative, locally advanced or advanced breast cancer after endocrine therapy has reached the primary research endpoint.


    This phase III clinical trial (SHR6390-III-301) is an evaluation of SHR6390 combined with fulvestrant versus placebo combined with fulvestrant in the treatment of HR-positive, HER2-negative locally advanced or late metastatic disease after previous endocrine therapy.


    The primary research endpoint of the trial is progression-free survival (PFS) assessed according to the RECISTv1.


    A total of 361 subjects were enrolled in the trial, randomly enrolled according to 2:1, and received SHR6390 or placebo combined with fulvestrant, every 28 days as a treatment cycle, of which SHR6390 or placebo was taken continuously in the first 3 weeks, and then One week of rest (without medication), treatment until disease progression, intolerable toxicity, or other conditions that require termination of treatment.


    At present, four CDK4/6 inhibitors have been approved globally, namely Pfizer’s palbociclib (pibaciclib), Novartis’s Ribociclib, Eli Lilly’s Abemaciclib and G1 Therapeutics’ Trilaciclib ( Domestic authorized to Simcere Pharmaceuticals).


    At present, Pfizer Pipercill (trade name: Aiboxin) and Eli Lilly’s Abbeceil (trade name: Weizhe) have been approved in China; among them, the first domestic copy of piperacill has been taken first by Qilu.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.